GlassScriptPhysician profile
Meredith Rages
NPI 1518469931
$1,583.25
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $796 · 2023: $747 · 2024: $40.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $185.39 | 2023-2024 | |
| Daiichi Sankyo INC. | $178.15 | 2022-2023 | Injectafer |
| Amgen INC. | $176.00 | 2022-2023 | Prolia, Evenity, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.60 | 2022-2023 | Jardiance, Tradjenta, Spiriva Respimat |
| Lilly USA, LLC | $138.48 | 2022-2023 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $112.51 | 2022-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $102.88 | 2022-2023 | Trintellix |
| Janssen Scientific Affairs, LLC | $74.14 | 2023 | Xarelto |
| Teva Pharmaceuticals USA, INC. | $62.84 | 2022 | |
| Abbvie INC. | $48.42 | 2022 | |
| Exact Sciences Corporation | $32.11 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $32.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.99 | 2022 | |
| Novo Nordisk INC | $28.56 | 2023 | Wegovy |
| Kowa Pharmaceuticals America, INC. | $24.89 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.18 | 2022 | |
| Sumitomo Pharma America, INC. | $19.04 | 2023 | Gemtesa |
| Scilex Pharmaceuticals INC. | $17.66 | 2023 | Ztlido |
| Janssen Pharmaceuticals, INC | $17.22 | 2023 | Xarelto |
| Merck Sharp & Dohme LLC | $15.68 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.83 | 2022 | |
| Viiv Healthcare Company | $14.63 | 2022 | |
| Glaxosmithkline, LLC. | $14.14 | 2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $13.65 | 2023 | |
| Acerus Pharmaceuticals Corporation | $13.64 | 2022 | |
| Amarin Pharma, INC. | $13.46 | 2022 | |
| Dexcom, INC. | $13.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Rages listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.